IRTC IRhythm Technologies Inc.

iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) --  (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023.

“On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors,” said Quentin Blackford, iRhythm’s President and CEO. “Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering results and building sustainable long-term value within healthcare will further strengthen our Board’s depth of expertise and unique perspectives as we continue to scale on a global basis.”

With their appointment to the Board of Directors, both Ms. Poul and Mr. Yoor have also been appointed to serve as members of the Company’s Audit Committee. These additions expand iRhythm’s Board to nine directors, eight of whom are independent members.

“Mojdeh is an accomplished, purpose-driven healthcare executive and is recognized for her experience in accelerating growth through portfolio transformation and reliably delivering results through diverse, high-performance leadership teams. Brian is a seasoned global financial executive and has led multi-national companies through transformative periods that have led to sustainable financial strength, business growth and value creation,” said Abhi Talwalkar, Chairman of the Board of Directors. “Mojdeh and Brian’s deep industry knowledge and experience will be invaluable in guiding us to grow our business, efficiently scale our operations and deliver on the significant growth opportunity ahead.”

About Mojdeh Poul

Mojdeh Poul is an accomplished healthcare executive with over thirty years of extensive experience leading global businesses and operations in large multinational organizations. Most recently, Ms. Poul served as the Executive Vice President and Group President of 3M Healthcare Business from April 2019 to June 2022. In this role, she led the global P&L, strategy, manufacturing and commercial operations, and R&D for the $8.6B Healthcare Business Group. Ms. Poul joined 3M in April of 2011 and held multiple leadership roles throughout her tenure, including as Executive Vice President of Safety & Graphics Business Group, as President of 3M Canada, and as President of two divisions within the 3M Healthcare Business Group.

Prior to 3M, Ms. Poul held global business leadership roles of increasing responsibility with leading global medical technology companies, including Medtronic, ev3, Boston Scientific, and Teleflex Medical. In these roles, she led formulation and implementation of market development strategies to drive global growth and penetration of neuromodulation and emerging cardiovascular therapies. Deployed strategies included generation of world class clinical evidence and health economics data, physician education and referral development programs, and direct to patient marketing.

Ms. Poul has served on the Board of Stanley Black and Decker since February of 2021, where she is a member of the Audit and Talent & Compensation Committees. She holds an MBA from University of North Carolina at Chapel Hill as well as a Master of Engineering and Bachelor of Science in Mechanical Engineering from University of Louisville.

About Brian Yoor

Brian Yoor is an accomplished global financial executive with over three decades of leadership experience in strategy, finance, operations, investor relations, acquisitions and integrations, and organizational development for healthcare and start-up companies. Brian spent most of his career at Abbott, where he concluded his career as Chief Financial Officer. Prior to that, he held multiple leadership roles including Division Controller for multiple business units, and Vice President of investor relations. During his tenure at Abbott, Brian successfully built and led a performance culture and transformative change in the areas of capital allocation, enterprise-wide cash flow, and investor relations.

Mr. Yoor serves as Chairman of the Board for Covira Surgical, a biotech start-up in the microbiome space, and he previously served as the founding Chairman and an Operating Partner at Portal Innovations, a unique venture capital company for early life science start-ups. He attended the University of Toledo, where he earned his Bachelor of Business Administration in Accounting.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements relating to growth expectations and personnel matters. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact

Stephanie Zhadkevich

(919) 452-5430

Media Contact

Saige Smith

(262) 289-7065



EN
06/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

 PRESS RELEASE

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlig...

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to tho...

 PRESS RELEASE

第18回アジア太平洋不整脈学会学術大会(APHRS2025)で発表された新たなデータにより アジア人集団におけるiRhythm社のZio長期...

第18回アジア太平洋不整脈学会学術大会(APHRS2025)で発表された新たなデータにより アジア人集団におけるiRhythm社のZio長期連続モニタリングの性能が明らかに iRhythm Technologies, Inc.は、アジア太平洋不整脈学会学術大会(APHRS2025)と第71回日本不整脈心電学会学術大会(JHRS2025)の合同学術集会において新しいデータを発表しました。40万人を超える患者を対象とした大規模解析 1 により、長期間の心電図(ECG)モニタリングの性能の一貫性と一般化可能性が裏付けられました。アジア人患者(コホートの3.4%)における中央値の装着時間および解析可能時間は非アジア人患者と同等であり、この結果は既発表のCAMELOT研究2 およびAVALON研究3 で報告されたZio LTCMの性能と一致していました。 サンフランシスコ, Nov. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) は2025年11月12日から15日まで日本・横浜で開催された第18回アジア太平洋不整脈学会(APHRS)/第71回日本不整脈心電学会学術大会(JHRS2025)合同学術集会において、口頭発表セッションで新たなデータを発表したと明らかにしました。 河田 宏医師の主導のもと、研究チームは米国の大規模患者コホートを対...

 PRESS RELEASE

iRhythm Technologies Announces Publication of Large-Scale Study in Hea...

iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025 Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio® long-term continuous monitoring (LTCM)– even in patients with frequent (i.e., daily) symptoms1Data from more than 742,000 patients presented at the American Heart Association (AHA) Scientific Sessions 2025 confirm that at-home self-application and activation of Zio 14-day patc...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wolfe Research 2025 Healthcare Conference on Tuesday, November 18, 2025, at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time)Jefferies 2025 Global Healthcare Conference on Thursday, November 20, 2025, at 9:30 a.m. Greenwich Mean Time (1:30...

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 8,000 shares at 207.440USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch